Lu-177 PSMA Therapy Shows Promise in Early-Stage Prostate Cancer: LUNAR Trial Dosimetry Analysis

MedAI Digest
MedAI Digest
Lu-177 PSMA Therapy Shows Promise in Early-Stage Prostate Cancer: LUNAR Trial Dosimetry Analysis
Loading
/

A secondary analysis of the LUNAR trial reveals that neoadjuvant 177Lu-PSMA-I&T delivers well-tolerated radiation doses while significantly improving progression-free survival in patients with low-volume oligometastatic prostate cancer when combined with stereotactic radiotherapy.

Original paper: Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. — Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 10.2967/jnumed.125.271467

📄 Read the article

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA


Trending now

Quantitative pathology and APOE genotype reveal dementia risk and progression in Lewy body disease.
APOE Genotype and Protein Pathology Shape Dementia Risk in Lewy Body Disease
Transfer-learning guided design of high-performance conjugated polymers for low-voltage electrochemical transistors.
Machine Learning Accelerates Discovery of Ultra-Low-Voltage Polymers
AI-guided multi-omics analysis identifies NPC1-modulated susceptibility to SARS-CoV-2 infection under PM2.5 exposure.
Air Pollution and COVID-19: How NPC1 Mediates SARS-CoV-2 Infection Risk
Personalized artificial intelligence based left ventricular ejection fraction and systolic dysfunction assessment.
ECG-Based AI Models Enable Cost-Effective Cardiac Function Assessment